sykho
My impression is that China is making huge investments in cleaning up the country. Increasingly China has begun to assert itself and not allowing itself to be a dumping ground goes along with this change.
From [1] it appears that U.S. sales for pharmaceuticals are double the figure for the EU. This suggests that advertising, lack of regulatory controls on pricing, and R&D account for this. Since medical costs are exspensive in the U.S. at the point of contact and the U.S. spends twice per capita GDP on healthcare people are indignant at the system and things like direct to consumer advertising is an easy target for our ire.
I don’t know if English is your native language but “marketing spend” is correct and “marketing spending” is not.
[1] https://www.efpia.eu/media/361960/efpia-pharmafigures2018_v0...
The current system seems to incentivize companies to hold on to patents by making minor, insignificant changes to drugs to maximize profits. They are incentivized to ignored exotic diseases that have too small of a market share for each individual disease but affect, collectively, a lot of people. There is also the fact that in a system like the U.S. where people have large out of pocket expenses at the point of contact with the health care system having companies maximize profits for a particular life saving drug causes some people to view said maximization with disgust.